{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:16Z","timestamp":1772119336026,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-024-04747-z","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:42:39Z","timestamp":1732063359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic Value of Baseline Skeletal Muscle Index in Colorectal Cancer Patients Treated with Fruquintinib: A multi-center real world analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Wanfen","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fakai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuerong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penghai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangrong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingliang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiusheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"issue":"3","key":"4747_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.6004\/jnccn.2022.7082","volume":"21","author":"C Nevala-Plagemann","year":"2023","unstructured":"Nevala-Plagemann C, Sama S, Ying J et al (2023) A real-world comparison of Regorafenib and Trifluridine\/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw 21(3):257\u2013264. https:\/\/doi.org\/10.6004\/jnccn.2022.7082","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4747_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.clcc.2021.06.002","volume":"20","author":"P Vitale","year":"2021","unstructured":"Vitale P, Zanaletti N, Famiglietti V et al (2021) Retrospective study of Regorafenib Versus TAS-102 efficacy and safety in Chemorefractory metastatic colorectal Cancer (mCRC) patients: a multi-institution Real Life Clinical Data. Clin Colorectal Cancer 20(3):227\u2013235. https:\/\/doi.org\/10.1016\/j.clcc.2021.06.002","journal-title":"Clin Colorectal Cancer"},{"key":"4747_CR3","doi-asserted-by":"publisher","first-page":"oyae235","DOI":"10.1093\/oncolo\/oyae235","volume":"7","author":"KY Hsiao","year":"2024","unstructured":"Hsiao KY, Chen HP, Rau KM et al (2024) Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine\/tipiracil or regorafenib. Oncologist 7:oyae235. https:\/\/doi.org\/10.1093\/oncolo\/oyae235","journal-title":"Oncologist"},{"issue":"5","key":"4747_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"4747_CR5","doi-asserted-by":"publisher","unstructured":"Ni J, Zhang L (2020) Cancer Cachexia: Definition, Staging, and Emerging Treatments. Cancer Manag Res 12:5597\u20135605. https:\/\/doi.org\/10.2147\/CMAR.S261585","DOI":"10.2147\/CMAR.S261585"},{"issue":"8","key":"4747_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","volume":"21","author":"S Antoun","year":"2010","unstructured":"Antoun S, Baracos VE, Birdsell L et al (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21(8):1594\u20131598. https:\/\/doi.org\/10.1093\/annonc\/mdp605","journal-title":"Ann Oncol"},{"issue":"2","key":"4747_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clcc.2019.04.003","volume":"18","author":"F Huemer","year":"2019","unstructured":"Huemer F, Schlintl V, Hecht S et al (2019) Regorafenib is Associated with increased skeletal muscle loss compared to TAS-102 in metastatic colorectal Cancer. Clin Colorectal Cancer 18(2):159-166e3. https:\/\/doi.org\/10.1016\/j.clcc.2019.04.003","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"4747_CR8","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.1038\/s41598-017-07955-6","volume":"7","author":"W Gu","year":"2017","unstructured":"Gu W, Wu J, Liu X et al (2017) Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients. Sci Rep 7(1):7587. https:\/\/doi.org\/10.1038\/s41598-017-07955-6","journal-title":"Sci Rep"},{"issue":"1","key":"4747_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cam4.1909","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K et al (2019) Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med 8(1):137\u2013146. https:\/\/doi.org\/10.1002\/cam4.1909","journal-title":"Cancer Med"},{"key":"4747_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.urology.2017.05.056","volume":"108","author":"L Ch\u00e9ry","year":"2017","unstructured":"Ch\u00e9ry L, Borregales LD, Fellman B et al (2017) The effects of Neoa djuvant axitinib on anthropometric parameters in patients with locally advanced non-metastatic renal cell carcinoma. Urology 108:114\u2013121. https:\/\/doi.org\/10.1016\/j.urology.2017.05.056","journal-title":"Urology"},{"issue":"3","key":"4747_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315(3):971\u2013979. https:\/\/doi.org\/10.1124\/jpet.105.084145","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 5","key":"4747_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0959-8049(02)80597-4","volume":"38","author":"T Pawson","year":"2002","unstructured":"Pawson T (2002) Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38(Suppl 5):S3-10. https:\/\/doi.org\/10.1016\/s0959-8049(02)80597-4","journal-title":"Eur J Cancer"},{"issue":"24","key":"4747_CR13","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu RH et al (2018) Effect of Fruquintinib vs Placebo on overall survival in patients with previously treated metastatic colorectal Cancer: the FRESCO Randomized Clinical Trial. JAMA 319(24):2486\u20132496. https:\/\/doi.org\/10.1001\/jama.2018.7855","journal-title":"JAMA"},{"issue":"24","key":"4747_CR14","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.2217\/fon-2021-0202","volume":"17","author":"A Dasari","year":"2021","unstructured":"Dasari A, Sobrero A, Yao J et al (2021) FRESCO-2: a global phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol 17(24):3151\u20133162. https:\/\/doi.org\/10.2217\/fon-2021-0202","journal-title":"Future Oncol"},{"issue":"1","key":"4747_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","volume":"85","author":"N Mitsiopoulos","year":"1998","unstructured":"Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85(1):115\u2013122. https:\/\/doi.org\/10.1152\/jappl.1998.85.1.115","journal-title":"J Appl Physiol (1985)"},{"issue":"4","key":"4747_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01635581.2014.894103","volume":"66","author":"M Barret","year":"2014","unstructured":"Barret M, Antoun S, Dalban C et al (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66(4):583\u2013589. https:\/\/doi.org\/10.1080\/01635581.2014.894103","journal-title":"Nutr Cancer"},{"issue":"3","key":"4747_CR17","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s13277-015-4008-8","volume":"37","author":"C Jian-Hui","year":"2016","unstructured":"Jian-Hui C, Iskandar EA, Cai SI et al (2016) Significance of Onodera\u2019s prognostic nutritional index in patients with colorectal cancer: a large cohort study in a single Chinese institution. Tumour Biol 37(3):3277\u20133283. https:\/\/doi.org\/10.1007\/s13277-015-4008-8","journal-title":"Tumour Biol"},{"issue":"2","key":"4747_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"3","key":"4747_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0167-8140(02)00404-8","volume":"66","author":"A Trotti","year":"2003","unstructured":"Trotti A, Bellm LA, Epstein JB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66(3):253\u2013262. https:\/\/doi.org\/10.1016\/s0167-8140(02)00404-8","journal-title":"Radiother Oncol"},{"issue":"6","key":"4747_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jamaoncol.2015.6339","volume":"2","author":"AJ Grossberg","year":"2016","unstructured":"Grossberg AJ, Chamchod S, Fuller CD et al (2016) Association of Body Composition with Survival and Locoregional Control of Radiotherapy-Treated Head and Neck squamous cell carcinoma. JAMA Oncol 2(6):782\u2013789. https:\/\/doi.org\/10.1001\/jamaoncol.2015.6339","journal-title":"JAMA Oncol"},{"issue":"12","key":"4747_CR21","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, Verheul HM (2016) Loss of muscle Mass during Chemotherapy is predictive for poor survival of patients with metastatic colorectal Cancer. J Clin Oncol 34(12):1339\u20131344. https:\/\/doi.org\/10.1200\/JCO.2015.63.6043","journal-title":"J Clin Oncol"},{"issue":"1","key":"4747_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clnu.2023.11.009","volume":"43","author":"Z Lilong","year":"2024","unstructured":"Lilong Z, Kuang T, Li M, Li X, Hu P, Deng W, Wang W (2024) Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers. Clin Nutr 43(1):31\u201341. https:\/\/doi.org\/10.1016\/j.clnu.2023.11.009","journal-title":"Clin Nutr"},{"key":"4747_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB et al (2016) Prognostic value of Sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"},{"issue":"9","key":"4747_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0297","volume":"85","author":"J Wang","year":"2024","unstructured":"Wang J, Chen Y, He J, Yin C, Xie M (2024) Sarcopenia predicts postoperative complications and survival of Colorectal Cancer patients undergoing radical surgery. Br J Hosp Med (Lond) 85(9):1\u201317. https:\/\/doi.org\/10.12968\/hmed.2024.0297","journal-title":"Br J Hosp Med (Lond)"},{"issue":"4","key":"4747_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/jso.27315","volume":"128","author":"G Nagarajan","year":"2023","unstructured":"Nagarajan G, Doshi P, Bardeskar NS, Kulkarni A, Punamiya A, Tongaonkar H (2023) Association between Sarcopenia and postoperative complications in patients undergoing surgery for gastrointestinal or hepato-pancreatico-biliary cancer. J Surg Oncol 128(4):682\u2013691. https:\/\/doi.org\/10.1002\/jso.27315","journal-title":"J Surg Oncol"},{"issue":"1","key":"4747_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/SLA.0000000000002679","volume":"268","author":"C Simonsen","year":"2018","unstructured":"Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, Svendsen LB, Christensen JF (2018) Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology: a Meta-analysis. Ann Surg 268(1):58\u201369. https:\/\/doi.org\/10.1097\/SLA.0000000000002679","journal-title":"Ann Surg"},{"key":"4747_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00366","volume":"9","author":"DW Ma","year":"2019","unstructured":"Ma DW, Cho Y, Jeon MJ et al (2019) Relationship between Sarcopenia and Prognosis in Patient with Concurrent Chemo-Radiation Therapy for Esophageal Cancer. Front Oncol 9:366. https:\/\/doi.org\/10.3389\/fonc.2019.00366","journal-title":"Front Oncol"},{"issue":"3","key":"4747_CR28","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.clnu.2019.03.014","volume":"39","author":"E Chung","year":"2020","unstructured":"Chung E, Lee HS, Cho ES et al (2020) Prognostic significance of Sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancer. Clin Nutr 39(3):820\u2013828 Epub 2019 Mar 19","journal-title":"Clin Nutr"},{"issue":"18","key":"4747_CR29","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.28798","volume":"120","author":"SP Psutka","year":"2014","unstructured":"Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, Stewart SB, Thapa P, Tarrell RF, Cheville JC, Tollefson MK (2014) Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 120(18):2910\u20132918. https:\/\/doi.org\/10.1002\/cncr.28798","journal-title":"Cancer"},{"issue":"4","key":"4747_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/jhn.12649","volume":"32","author":"M S\u00e1nchez","year":"2019","unstructured":"S\u00e1nchez M, Castro-Eguiluz D, Luvi\u00e1n-Morales J et al (2019) Deterioration of nutritional status of patients with locally advanced cervical cancer during treatment with concomitant chemoradiotherapy. J Hum Nutr Diet 32(4):480\u2013491. https:\/\/doi.org\/10.1111\/jhn.12649","journal-title":"J Hum Nutr Diet"},{"issue":"4","key":"4747_CR31","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00280-019-03779-5","volume":"83","author":"O K\u00f6stek","year":"2019","unstructured":"K\u00f6stek O, Y\u0131lmaz E, Hac\u0131o\u011flu MB et al (2019) Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Cancer Chemother Pharmacol 83(4):735\u2013742. https:\/\/doi.org\/10.1007\/s00280-019-03779-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"4747_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/1055-9965.EPI-17-0200","volume":"26","author":"BJ Caan","year":"2017","unstructured":"Caan BJ, Meyerhardt JA, Kroenke CH et al (2017) Explaining the obesity Paradox: the Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev 26(7):1008\u20131015. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0200","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"4747_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00384-018-3128-1","volume":"33","author":"G Sun","year":"2018","unstructured":"Sun G, Li Y, Peng Y et al (2018) Can Sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis. Int J Colorectal Dis 33(10):1419\u20131427. https:\/\/doi.org\/10.1007\/s00384-018-3128-1","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"4747_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/jso.24064","volume":"112","author":"JL Van Vugt","year":"2015","unstructured":"Van Vugt JL, Levolger S, Coelen RJ et al (2015) The impact of Sarcopenia on survival and complications in surgical oncology: A review of the current literature. J Surg Oncol 112(6):681\u2013682. https:\/\/doi.org\/10.1002\/jso.24064","journal-title":"J Surg Oncol"},{"issue":"4","key":"4747_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1017\/S0029665118000423","volume":"77","author":"E Cespedes Feliciano","year":"2018","unstructured":"Cespedes Feliciano E, Chen WY (2018) Clinical implications of low skeletal muscle mass in early-stage breast and colorectal cancer. Proc Nutr Soc 77(4):382\u2013387. https:\/\/doi.org\/10.1017\/S0029665118000423","journal-title":"Proc Nutr Soc"},{"issue":"6","key":"4747_CR36","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/jcsm.12831","volume":"12","author":"J McGovern","year":"2021","unstructured":"McGovern J, Dolan RD, Horgan PG et al (2021) Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle 12(6):1408\u20131417. https:\/\/doi.org\/10.1002\/jcsm.12831","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4747_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bcp.2018.07.001","volume":"155","author":"VL Damaraju","year":"2018","unstructured":"Damaraju VL, Kuzma M, Cass CE et al (2018) Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes. Biochem Pharmacol 155:162\u2013171. https:\/\/doi.org\/10.1016\/j.bcp.2018.07.001","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"4747_CR38","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.21873\/anticanres.14417","volume":"40","author":"M Amanuma","year":"2020","unstructured":"Amanuma M, Nagai H, Igarashi Y (2020) Sorafenib might induce Sarcopenia in patients with Hepatocellular Carcinoma by inhibiting carnitine absorption. Anticancer Res 40(7):4173\u20134182. https:\/\/doi.org\/10.21873\/anticanres.14417","journal-title":"Anticancer Res"},{"key":"4747_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","volume":"407","author":"L Adnane","year":"2006","unstructured":"Adnane L, Trail PA, Taylor I et al (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol 407:597\u2013612. https:\/\/doi.org\/10.1016\/S0076-6879(05)07047-3","journal-title":"Methods Enzymol"},{"issue":"10","key":"4747_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/nu12103101","volume":"12","author":"E Rinninella","year":"2020","unstructured":"Rinninella E, Cintoni M, Raoul P et al (2020) Skeletal muscle loss during multikinase inhibitors therapy: Molecular pathways, clinical implications, and Nutritional challenges. Nutrients 12(10):3101. https:\/\/doi.org\/10.3390\/nu12103101","journal-title":"Nutrients"},{"issue":"10","key":"4747_CR41","doi-asserted-by":"publisher","first-page":"E1042","DOI":"10.1152\/ajpendo.00410.2012","volume":"304","author":"JP White","year":"2013","unstructured":"White JP, Puppa MJ, Gao S et al (2013) Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab 304(10):E1042\u2013E1052. https:\/\/doi.org\/10.1152\/ajpendo.00410.2012","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04747-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04747-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04747-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:01:43Z","timestamp":1736348503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04747-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4747"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04747-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4969712\/v1","asserted-by":"object"}]},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"21 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"186"}}